A global pharmaceutical company had a Phase II/III enzyme replacement therapy in development for a rare genetic disorder that targeted symptoms not addressed by current standard of care.

We are delighted to welcome Mattia Belloni as a Senior Consultant at Windrose.

Windrose conducted a pricing, market access and evidence gap assessment across US, EU4 and UK for two novel agents in a muscle weakness disorder

On the 9th March Windrose ran a 1-day workshop for the masters students on the Cambridge University MPhil in Therapeutic Sciences course. The content included ‘Why it’s important to get your P&MA right’, delved into stakeholder decision analysis, the various payer systems & market archetypes, how to optimise the global strategy and communicate value.

This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.

We are pleased to announce that Agatha Cimbalova and Anjalina Mitra have been promoted to Senior Analysts. This promotion is a recognition of Agatha and Anjie’s dedication, hard work, and great progression that has been observed over their time working at Windrose.

Congratulations!

Our client was evaluating an orphan indication for Product X, which is currently indicated for another orphan indication in Europe, Japan, and Latin America.

Download the report to find out about the German pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out how pricing and reimbursement decisions are made in The Netherlands, including, Payer Evaluation, Price setting and reimbursement

Download the report to find out how pricing and reimbursement decisions are made in Spain, including, Payer Evaluation, Price setting and reimbursement

Our client has a successful JAK inhibitor, “Product X”, which has large volumes of sales in the US; Product X sales are expected to continue to grow in the EU5, particularly through indication expansion.

As a third installment of our Aduhelm coverage, we look at the recently announced draft National Coverage Determination (NCD) by the Centers for Medicare and Medicaid Services (CMS).

Our client had a novel oral anticoagulant (NOAC) indicated for thromboembolic disorders on the market, which had seen significant commercial success and sales growth since its launch.

Our client had to make a business development decision regarding a potential new asset which would be developed in ulcerative colitis (UC) and atopic dermatitis (AtD).

Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialisation strategy

Windrose Consulting Group are pleased to continue the New Year with two new Consultants joining our growing team. Muna Ali and Stacey McDonald

Windrose Consulting Group are pleased bring in the New Year with two new Analysts on our team and a promotion within the team.

Emerging Markets are not only influential in their own regions but represent a significant proportion of the world’s population and trade. They also represent a growing share of global healthcare spending. As such they offer an attractive growth prospect for the pharmaceutical industry.

December 1st is World AIDS Day and is an opportunity to reflect on pharmacological innovations that has turned a once fatal disease into a treatable condition. Infection rates have slowed in recent years due to increase in testing availability, as well as development of antiretroviral therapy and, more recently, pre-exposure prophylaxis (PrEP)

We are pleased to launch the first edition of our Windrose Consulting Group: Global News Roundup for Q1-Q3 2021.